View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
June 11, 2020

Namilumab and Infliximab selected for CATALYST trial in UK

The Universities of Birmingham and Oxford in the UK have partnered with Izana Bioscience and Celltrion Healthcare for the CATALYST clinical trial, which is assessing drug candidates to treat Covid-19 in hospitalised patients.

The Universities of Birmingham and Oxford in the UK have partnered with Izana Bioscience and Celltrion Healthcare for the CATALYST clinical trial, which is assessing drug candidates to treat Covid-19 in hospitalised patients.

CATALYST is being performed in alliance with University Hospitals Birmingham NHS Foundation Trust (UHB) and the Birmingham National Institute for Health Research Biomedical Research Centre (NIHR BRC).

Izana Bioscience will provide its drug candidate, Namilumab (IZN-101), as the first of four potential treatments to be evaluate in the trial.

Namilumab is a fully human monoclonal antibody currently in late-stage trials for the treatment of rheumatoid arthritis and ankylosing spondylitis. It acts on granulocyte-macrophage colony stimulating factor (GM-CSF), which is naturally produced by immune cells in the body.

At abnormal levels, GM-CSF is believed to result in the excessive and dangerous lung inflammation observed in Covid-19 patients.

Celltrion Healthcare UK will provide its anti-tumour necrosis factor (TNF) therapy, Infliximab (CT-P13), which binds to a protein involved in inflammation.

Under the brand name Remsima, Infliximab is indicated to treat inflammatory conditions, including eight autoimmune diseases, such as rheumatoid arthritis and irritable bowel syndrome.

These drugs are expected to decrease the severity of the disease, reducing the number of patients being admitted to intensive care and virus-related deaths.

CATALYST trial co-clinical investigator Dr Ben Fisher said: “In the CATALYST study we hope to show with a single dose of these kinds of drugs in hospitalised patients that we are able to delay or prevent the rapid deterioration into intensive care and requirement for invasive ventilation in this critical patient group.

“We hope that by using a treatment that is already used to treat inflammation in other autoimmune conditions we may be able to manage inflammation associated with Covid-19 early.”

The trial is designed to enrol up to 40 patients to each arm. The effectiveness of each drug will be determined by the amount of oxygen in the blood and other disease severity indicators.

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU